Impaired phagocyte oxidative capacity in human immunodeficiency virus-infected children.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Impaired phagocyte oxidative capacity in human immunodeficiency virus-infected children.

J Infect Dis. 1999 Mar;179(3):584-9. Unique Identifier : AIDSLINE MED/99137793
Hayani KC; Verral SC; Pitrak DL; Division of Pediatric Infectious Diseases, Department of; Pediatrics, University of Illinois College of Medicine at; Chicago, Chicago, IL 60612-7324, USA. U12017@UIC.edu

Abstract: Children infected with the human immunodeficiency virus (HIV) have T helper cell deficiency, but frequent bacterial infections suggest phagocyte dysfunction. Whole blood chemiluminescence (CL) assays were used to measure the respiratory burst capacity of phagocytes from HIV-infected children, perinatally HIV-exposed but uninfected children, and normal healthy children. Phagocytes were stimulated by zymosan opsonized with human complement with and without priming by platelet-activating factor (PAF) or FMLP. Activities of enzymes involved in the respiratory burst, oxidase and myeloperoxidase, were examined after opsonin receptor-independent stimulation with PMA. Unprimed CL responses to opsonized zymosan were decreased for HIV-infected children with severe CD4 lymphocyte suppression compared with healthy children (P=.03), and PAF-primed CL responses to opsonized zymosan were decreased in HIV-infected children with both moderate and severe CD4 lymphocyte suppression (P=.02 and P=.01, respectively), despite normal or increased activities of the respiratory burst enzymes. These impairments may contribute to secondary bacterial infections.

Keywords: JOURNAL ARTICLE Adolescence Analysis of Variance Chemiluminescence Child Child, Preschool Complement/IMMUNOLOGY Female Human HIV/*IMMUNOLOGY HIV Infections/BLOOD/*IMMUNOLOGY Immunity, Natural In Vitro Male Peroxidase/BLOOD Phagocytes/DRUG EFFECTS/*PHYSIOLOGY Platelet Activating Factor/PHARMACOLOGY Reference Values *Respiratory Burst Risk Factors Support, Non-U.S. Gov't
990630
A9960914

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .